# Scientific Synthesis and Evaluation
## Hypothesis Summary
The hypothesis proposes that pharmacological activation of TREM2 on microglia will enhance clearance of extracellular tau aggregates, potentially slowing neurodegeneration in tauopathies such as Alzheimer's disease. The mechanism involves TREM2/DAP12 signaling, which promotes actin reorganization, phagocytic receptor expression, and lysosomal biogenesis—all supporting a neuroprotective microglial response.
---
## Dimension Scores
| Dimension | Score | Rationale |
|-----------|-------|-----------|
| **Mechanistic Plausibility** | 0.72 | TREM2 signaling cascade is well-characterized; connection to phagocytosis documented. **Critical gap**: Direct tau-TREM2 binding has not been demonstrated. |
| **Evidence Strength** | 0.75 | Strong human genetics (R47H, loss-of-function variants); solid mouse model data linking TREM2 to tau pathology phenotypes; **weak direct evidence** for the specific extracellular tau phagocytosis mechanism. |
| **Novelty** | 0.55 | TREM2 as a therapeutic target is well-explored; multiple antibodies in development; the specific tau-clearance angle offers moderate incremental novelty. |
| **Feasibility** | 0.70 | Downstream readouts (phagocytosis, signaling markers) are measurable; distinguishing tau-specific effects